ACADIA to Host Conference Call and Webcast on Tuesday, March 6,2007, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Feb. 27, 2007—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report its unaudited financial results for the fourth quarterand year ended December 31, 2006 on Tuesday, March 6, 2007, after theU.S. financial markets close. ACADIA's management will host aconference call and webcast on Tuesday, March 6, 2007 at 5:00 p.m.Eastern Time to discuss ACADIA's financial results and developmentprograms.
The conference call may be accessed by dialing 866-700-7173 forparticipants in the U.S. or Canada and 617-213-8838 for internationalcallers (reference passcode 55576242). A telephone replay of theconference call may be accessed through March 20, 2007 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 28337764). The conferencecall also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archivedthere until March 20, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive clinical programs as well as a portfolio of preclinical anddiscovery assets directed at large unmet medical needs, includingschizophrenia, Parkinson's disease psychosis, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.